Article
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.
Department of Urology, Medical University Innsbruck, Austria.
BJU International (impact factor:
2.84).
05/2008;
101(10):1223-6.
DOI:10.1111/j.1464-410X.2007.07367.x
pp.1223-6
Source: PubMed
-
Citations (0)
- Cited In (2)
-
Article: Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.
[show abstract] [hide abstract]
ABSTRACT: The objective of this study was to update an in-depth analysis of the time trend for prostate cancer (PCA) mortality in the population of Tyrol by 5 years, namely to 2008. In Tyrol, prostate-specific antigen (PSA) tests were introduced in 1988/89; more than three-quarters of all men in the age group 45-74 had at least one PSA test in the past decade. We applied the same model as in a previous publication, i.e., an age-period-cohort model using Poisson regression, to the mortality data covering more than three decades from 1970 to 2008. For Tyrol from 2004 to 2008 in the age group 60+ period terms show a significant reduction in prostate cancer mortality with a risk ratio of 0.70 (95% confidence interval 0.57, 0.87) for Tyrol, and for Austria excluding Tyrol a moderate reduction with a risk ratio of 0.92 (95% confidence interval 0.87, 0.97), each compared to the mortality rate in the period 1989-1993. This update strengthens our previously published results, namely that PSA testing offered to a population at no charge can reduce prostate cancer mortality. The extent of mortality reduction is in line with that reported in the other recent publications. However, our data do not permit us to fully assess the harms associated with PCA screening, and no recommendation for PSA screening can be made without a careful evaluation of overdiagnosis and overtreatment.International Journal of Public Health 06/2011; 57(1):57-62. · 2.54 Impact Factor -
Article: Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.
International Journal of Public Health 11/2011; 57(1):45-7. · 2.54 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
1445 patients undergoing radical prostatectomy
extracapsular disease
Gleason score
over-diagnosis
patient age
patients
positive surgical margins
possible over-
prostate cancer
prostate-specific antigen
PSA level
PSA levels
PSA range
referral group
referral groups
referral population
screened group
screening programme
statistical significance
unscreened group